Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Paul E. Goss, Ph.D., M.B.,B.Ch.

TitleProfessor of Medicine
InstitutionMassachusetts General Hospital
DepartmentMedicine
AddressMassachusetts General Hospital
MGH Cancer Center, Cox Bldg., Suite 640
55 Fruit St
Boston MA 02114
Phone617/724-3118
Fax617/724-3166

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Goss PE, Ingle JN, Pritchard KI, Ellis MJ, Sledge GW, Budd GT, Rabaglio M, Ansari RH, Johnson DB, Tozer R, D'Souza DP, Chalchal H, Spadafora S, Stearns V, Perez EA, Liedke PE, Lang I, Elliott C, Gelmon KA, Chapman JA, Shepherd LE. Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27--A Randomized Controlled Phase III Trial. J Clin Oncol. 2013 Apr 10; 31(11):1398-404.
    View in: PubMed
  2. Higgins MJ, Liedke PE, Goss PE. Extended adjuvant endocrine therapy in hormone dependent breast cancer: The paradigm of the NCIC-CTG MA.17/BIG 1-97 trial. Crit Rev Oncol Hematol. 2013 Apr; 86(1):23-32.
    View in: PubMed
  3. Cheung AM, Tile L, Cardew S, Pruthi S, Robbins J, Tomlinson G, Kapral MK, Khosla S, Majumdar S, Erlandson M, Scher J, Hu H, Demaras A, Lickley L, Bordeleau L, Elser C, Ingle J, Richardson H, Goss PE. Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial. Lancet Oncol. 2012 Mar; 13(3):275-84.
    View in: PubMed
  4. Jin H, Tu D, Zhao N, Shepherd LE, Goss PE. Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover. J Clin Oncol. 2012 Mar 1; 30(7):718-21.
    View in: PubMed
  5. Pritchard KI, Shepherd LE, Chapman JA, Norris BD, Cantin J, Goss PE, Dent SF, Walde D, Vandenberg TA, Findlay B, O'Reilly SE, Wilson CF, Han L, Piura E, Whelan TJ, Pollak MN. Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14. J Clin Oncol. 2011 Oct 10; 29(29):3869-76.
    View in: PubMed
  6. Goss PE, Ingle JN, Alés-Martínez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, McTiernan A, Robbins J, Johnson KC, Martin LW, Winquist E, Sarto GE, Garber JE, Fabian CJ, Pujol P, Maunsell E, Farmer P, Gelmon KA, Tu D, Richardson H. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011 Jun 23; 364(25):2381-91.
    View in: PubMed
  7. Cigler T, Richardson H, Yaffe MJ, Fabian CJ, Johnston D, Ingle JN, Nassif E, Brunner RL, Wood ME, Pater JL, Hu H, Qi S, Tu D, Goss PE. A randomized, placebo-controlled trial (NCIC CTG MAP.2) examining the effects of exemestane on mammographic breast density, bone density, markers of bone metabolism and serum lipid levels in postmenopausal women. Breast Cancer Res Treat. 2011 Apr; 126(2):453-61.
    View in: PubMed
  8. LaCroix AZ, Powles T, Osborne CK, Wolter K, Thompson JR, Thompson DD, Allred DC, Armstrong R, Cummings SR, Eastell R, Ensrud KE, Goss P, Lee A, Neven P, Reid DM, Curto M, Vukicevic S. Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. J Natl Cancer Inst. 2010 Nov 17; 102(22):1706-15.
    View in: PubMed
  9. Goss PE, Chambers AF. Does tumour dormancy offer a therapeutic target? Nat Rev Cancer. 2010 Dec; 10(12):871-7.
    View in: PubMed
  10. Ingle JN, Schaid DJ, Goss PE, Liu M, Mushiroda T, Chapman JA, Kubo M, Jenkins GD, Batzler A, Shepherd L, Pater J, Wang L, Ellis MJ, Stearns V, Rohrer DC, Goetz MP, Pritchard KI, Flockhart DA, Nakamura Y, Weinshilboum RM. Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol. 2010 Nov 1; 28(31):4674-82.
    View in: PubMed
  11. Cigler T, Tu D, Yaffe MJ, Findlay B, Verma S, Johnston D, Richardson H, Hu H, Qi S, Goss PE. A randomized, placebo-controlled trial (NCIC CTG MAP1) examining the effects of letrozole on mammographic breast density and other end organs in postmenopausal women. Breast Cancer Res Treat. 2010 Apr; 120(2):427-35.
    View in: PubMed
  12. Goss PE. Atamestane and toremifene equal letrozole in TTP in advanced breast cancer -Concept of complete estrogen blockade may be revisited. The Oncology Report - Annually published (Aug) by Elsevier . 2009; In Press.
  13. Goss PE, Shangle Q, Haiqing H. Comparing the effects of atamestane, toremifene and tamoxifen alone and in combination, on bone serum lipids and iteris in ovariectomized rats. Journal of Steroid Biochemistry & Molecular Biology (RE-Submitted - 12/08- Accepted). 2009.
  14. Goss PE, Qi S, Hu H. Comparing the effects of atamestane, toremifene and tamoxifen alone and in combination, on bone, serum lipids and uterus in ovariectomized rats. J Steroid Biochem Mol Biol. 2009 Feb; 113(3-5):233-40.
    View in: PubMed
  15. LaCroix AZ, Cummings SR, Delmas P, Eastell R, Ensrud K, Reid DM, Vukicevic S, Armstrong RA, Thompson J, Thompson D, Wolter K, Allred C, Goss P, Osborne CK, Powles TJ . Effects of 5 Years of Treatment with Lasofoxifene on Incidence of Breast Cancer in Older Women. 2008 SABCS: General Session 1. 2008.
  16. Chambers AF, Goss PE. Putative growth characteristics of micrometastatic breast cancer. Breast Cancer Res. 2008; 10(6):114.
    View in: PubMed
  17. 2008.
  18. Chapman JW, Meng D, Shepherd L, Parulekar W, Ingle JN, Muss HB, Plamer M, Goss PE. Competing Causes of Death from a Randomized Trial of Extended Adjuvant Endocrine Therapy for Breast Cancer: NCIC CTG MA.17. Ehrlich II - 2nd World Conference on Magic Bullets (10/3/08-10/5/08). 2008.
  19. 2008.
  20. Goss PE, Muss HB, Ingle JN, Whelan TJ, Wu M. Extended adjuvant endocrine therapy in breast cancer: current status and future directions. Clin Breast Cancer. 2008 Oct; 8(5):411-7.
    View in: PubMed
  21. Goss PE. Extending the benefits of adjuvant therapy in early HR+ breast cancer. Breast Cancer Res Treat. 2008 Dec; 112 Suppl 1:45-52.
    View in: PubMed
  22. Joffe H, Partridge A, Giobbie-Hurder A, X Li, Goss P, Winer E, Garber J. Effect of augmentation of venlafaxine and SSRI with zolpidem on sleep and quality of life in breast cancer patients with hot flashes: A randomized double-blind placebo-controlled trial. 2008 ASCO Breast Cancer Symposium. 2008.
  23. 2008.
  24. 2008.
  25. 2008.
  26. Miller WR, Bartlett J, Brodie AM, Brueggemeier RW, di Salle E, Lønning PE, Llombart A, Maass N, Maudelonde T, Sasano H, Goss PE. Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? Oncologist. 2008 Aug; 13(8):829-37.
    View in: PubMed
  27. 2008.
  28. Goss PE. Reply to JCO/2008/172809,"A method to rest whether late extended letrozole, rather than self selection, improves the outcome in breast cancer patients who have completed 5 years of tamoxifen" by Jayant Vaidya [JCO/2008/173229]. J Clin Oncol. 2008; 26(19).
  29. Goss P, Allan AL, Rodenhiser DI, Foster PJ, Chambers AF. New clinical and experimental approaches for studying tumor dormancy: does tumor dormancy offer a therapeutic target? APMIS. 2008 Jul-Aug; 116(7-8):552-68.
    View in: PubMed
  30. Pater JL, Goss P, Meyer R. Stopping trials for benefit can (sometimes) benefit patients. J Clin Oncol. 2008 Jun 1; 26(16):2787-8; author reply 2788.
    View in: PubMed
  31. 2008.
  32. 2008.
  33. 2008.
  34. 2008.
  35. 2008.
  36. Ma XJ, Salunga R, Dahiya S, Wang W, Carney E, Durbecq V, Harris A, Goss P, Sotiriou C, Erlander M, Sgroi D. A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clin Cancer Res. 2008 May 1; 14(9):2601-8.
    View in: PubMed
  37. 2008.
  38. Ryan PD, Goss PE. Aromatase Inhibition in Breast Cancer: Update of Clinical Applications. Breast Cancer: Prognosis, Treatment and Prevention. 2008.
  39. 2008.
  40. Solomon SD, Wittes J, Finn PV, Fowler R, Viner J, Bertagnolli MM, Arber N, Levin B, Meinert CL, Martin B, Pater JL, Goss PE, Lance P, Obara S, Chew EY, Kim J, Arndt G, Hawk E. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation. 2008 Apr 22; 117(16):2104-13.
    View in: PubMed
  41. 2008.
  42. 2008.
  43. Muss HB, Tu D, Ingle JN, Martino S, Robert NJ, Pater JL, Whelan TJ, Palmer MJ, Piccart MJ, Shepherd LE, Pritchard KI, He Z, Goss PE. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17. J Clin Oncol. 2008 Apr 20; 26(12):1956-64.
    View in: PubMed
  44. Ingle JN, Tu D, Pater JL, Muss HB, Martino S, Robert NJ, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Goss PE. Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. Ann Oncol. 2008 May; 19(5):877-82.
    View in: PubMed
  45. Goss PE, Ingle JN, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Tu D. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol. 2008 Apr 20; 26(12):1948-55.
    View in: PubMed
  46. Goss PE. Addressing the future: combination with targeted therapies, adjuvant setting and beyond. Anticancer Drugs. 2008 Mar; 19 Suppl 2:S3-5.
    View in: PubMed
  47. Chapman JA, Meng D, Shepherd L, Parulekar W, Ingle JN, Muss HB, Palmer M, Yu C, Goss PE. Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer. J Natl Cancer Inst. 2008 Feb 20; 100(4):252-60.
    View in: PubMed
  48. Buzdar AU, Coombes RC, Goss PE, Winer EP. Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer. Cancer. 2008 Feb 1; 112(3 Suppl):700-9.
    View in: PubMed
  49. Come SE, Buzdar AU, Ingle JN, Johnston SR, Brodie AM, Coombes RC, Miller WR, Pritchard KI, Winer EP, Zujewski JA, Goss PE. Endocrine and targeted manipulation of breast cancer: summary statement for the Sixth Cambridge Conference. Cancer. 2008 Feb 1; 112(3 Suppl):673-8.
    View in: PubMed
  50. Sgroi D, Hameed O, Hattab E, Chang B, Moulis S, Steffel L, Salunga R, Ma X, Erlander M, Goss P; Medical School/MGH, Charlestown, MA; University of Alabama School of Medincine, Birmingham, AL; Indiana Univeersity, Indianapolis, IN; Scripps Memorial Hospital, LaJolla, CA; AviaraDx, San Diego, CA; Harvard Medical School/MGH, Boston, MA. Comparison of risk stratification of ER-positive, node-negative breast cancer patients by Oncotype DX versus molecular grade index and HOXB13/Il17BR ratio. ASCO. 2008.
  51. Ma, Erlander, Goss, Sgroi. POSTER#: A Robust Five-Gene RT-PCR Molecular Grade Index Stratifies Recurrence Risk for Grade 2 Tumors, Predicts Chemo-sensitivity and is Compatible with Formalin-fixed Paraffin-Embedded Tissue. 25TH Miami Breast Cancer Conference, Orlando. 2008.
  52. Ryan PD, Goss PE. The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer. Oncologist. 2008 Jan; 13(1):16-24.
    View in: PubMed
  53. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet. 2008; 371:29-40.
  54. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn H-J, & Panel Members. Proceedings of the 10th International Conference, 3/14 - 3/17/07, St. Gallen, Switzerland. The Breast. 2007; to be published Nov/Dec 2007.
  55. Gligorov J, Pritchard K, Goss PE. Adjuvant and extended adjuvant use of aromatase inhibitors: Reducing the risk of recurrence and distant metastasis. The Breast Supplement: St. Gallen (sponsored by Novartis Oncology). 2007; pending publication.
  56. Strasser-Weippl K, Goss PE. Chemoprevention of Breast Cancer. Manual of Breast Diseases by Manfred Kaufman & Ismail Jatoi (eds). Accepted commission to write on 6/7/07. 2007; Pending submission.
  57. Ryan PD, Goss PE. Aromatase inhibition in breast cancer:Update of clinical applications. Breast Cancer; Prognosis, Treatment, and Prevention (2nd edition); Pasqualini JR (ed). 2007; Chapter 24:submitted 3/2/07.
  58. Gligorov J, Pritchard K, Goss P. Adjuvant and extended adjuvant use of aromatase inhibitors: reducing the risk of recurrence and distant metastasis. Breast. 2007 Dec; 16 Suppl 3:S1-9.
    View in: PubMed
  59. Budzar AU, Coombes C, Goss PE, Winer EP. Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer. Proceedings of Sixth International Conference: Endocrine and Targeted Manipulation of Breast Cancer, 4/30 - 5/1/07, Cambridge, MA. 2007; to be published:to be published December 2007.
  60. Goss PE. MA.17. Proceedings of Sixth International Conference: Endocrine and Targeted Manipulation of Breast Cancer, 4/30 - 5/1/07, Cambridge, MA. 2007; to be published:to be published December 2007.
  61. Authors Order to be announced, Goss PE. Prevention: overview of recent studies. Proceedings of Sixth International Conference: Endocrine and Targeted Manipulation of Breast Cancer, 4/30 - 5/1/07, Cambridge, MA. 2007; to be published:to be published December 2007.
  62. Goss PE, Richardson H, Chlebowski R, Johnston D, Sarto GE, Maunsell E, Ingle JN, Alés-Martinez JE. National Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: evaluation of exemestane to prevent breast cancer in postmenopausal women. Clin Breast Cancer. 2007 Dec; 7(11):895-900.
    View in: PubMed
  63. 2007.
  64. Strasser-Weippl K, Goss PE. Hormonal Agents: Antiestrogens. Harrison's Manual of Oncology. 2007; Chapter 12:81-87.
  65. Strasser-Weipple K, Goss PE. Hormonal Agents: Antiestrogens. Harrison's Manual of Oncology. 2007; 81-87.
  66. 2007.
  67. 2007.
  68. Goss P, Bondarenko IN, Manikhas GN, Pendergrass KB, Miller WH, Langecker P, Blanchett D. Phase III, double-blind, controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cancer. J Clin Oncol. 2007 Nov 1; 25(31):4961-6.
    View in: PubMed
  69. 2007.
  70. Goss PE. Letrozole in the extended adjuvant setting: MA.17. Breast Cancer Res Treat. 2007; 105 Suppl 1:45-53.
    View in: PubMed
  71. Wu M, Goss PE. Update on the use of letrozole in breast cancer. Expert Opin Pharmacother. 2007 Oct; 8(14):2329-45.
    View in: PubMed
  72. 2007.
  73. Lee L, Pintilie M, Hodgson DC, Goss PE, Crump M. Screening mammography for young women treated with supradiaphragmatic radiation for Hodgkin's lymphoma. Ann Oncol. 2008 Jan; 19(1):62-7.
    View in: PubMed
  74. Goss P, Wu M. Application of aromatase inhibitors in endocrine responsive breast cancers. Breast. 2007 Dec; 16 Suppl 2:S114-9.
    View in: PubMed
  75. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn H-J, & Panel Members. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. 10th International Conference (3/12-3/17/07) St. Gallen, Switzerland. Ann Oncol (Special Article). 2007; 18:1133-1144.
  76. Moy B, Goss PE. Lapatinib-associated toxicity and practical management recommendations. Oncologist. 2007 Jul; 12(7):756-65.
    View in: PubMed
  77. 2007.
  78. Richardson H, Johnston D, Pater J, Goss P. The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial. Curr Oncol. 2007 Jun; 14(3):89-96.
    View in: PubMed
  79. Moy B, Kirkpatrick P, Kar S, Goss P. Lapatinib. Nat Rev Drug Discov. 2007 Jun; 6(6):431-2.
    View in: PubMed
  80. Moy B, Goss PE. Bone Integrity In Survivors of Breast Cancer. ASCO Educational Book. 2007; 529-533.
  81. Goss PE, von Eichel L. Summary of Aromatase Inhibitor Trials: The Past & Future. Special Issue: Journal of Steroid Biochemistry and Molecular Biology. 2007; In Press.
  82. 2007.
  83. Goss P, von Eichel L. Summary of aromatase inhibitor trials: the past and future. J Steroid Biochem Mol Biol. 2007 Aug-Sep; 106(1-5):40-8.
    View in: PubMed
  84. Santen RJ, Demers L, Ohorodnik S, Settlage J, Langecker P, Blanchett D, Goss PE, Wang S. Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy. Steroids. 2007 Jul; 72(8):666-71.
    View in: PubMed
  85. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL, NCIC CTG MA.17. Efficacy of Letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: NCIC CTG MA.17. 2007; 25(15):1957-9.
  86. 2007.
  87. Pater J, Tu D, Shepherd L, Ingle JN, Goss PE. Decision making in adjuvant trials in breast cancer: the NCIC CTG MA.17 trial as an example. Breast Cancer Res Treat. 2008 Mar; 108(2):265-9.
    View in: PubMed
  88. Cigler T, Goss PE. Breast cancer adjuvant endocrine therapy. Cancer J. 2007 May-Jun; 13(3):148-55.
    View in: PubMed
  89. Booth CM, Pater JL, Goss PE. Identifying breast cancer patients most likely to benefit from aromatase inhibitor therapy after adjuvant tamoxifen. Cancer. 2007 May 1; 109(9):1927-8; author reply 1928.
    View in: PubMed
  90. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. J Clin Oncol. 2007 May 20; 25(15):2006-11.
    View in: PubMed
  91. 2007.
  92. del Carmen MG, Halpern EF, Kopans DB, Moy B, Moore RH, Goss PE, Hughes KS. Mammographic breast density and race. AJR Am J Roentgenol. 2007 Apr; 188(4):1147-50.
    View in: PubMed
  93. 2007.
  94. 2007.
  95. 2007.
  96. Moy B, Goss PE. TEACH: Tykerb evaluation after chemotherapy. Clin Breast Cancer. 2007 Feb; 7(6):489-92.
    View in: PubMed
  97. Goss PE, Strasser-Weippl K, Qi S, Hu H. Effects of liarozole fumarate (R85246) in combination with tamoxifen on N-methyl-N-nitrosourea (MNU)-induced mammary carcinoma and uterus in the rat model. BMC Cancer. 2007; 7:26.
    View in: PubMed
  98. 2007.
  99. Moy B, Maltzman JD, Goss PE. P119 Phase III study of lapatinib after completion of adjuvant chemotherapy in trastuzumab-naive women with ErbB2-overexpressing breast cancer: Tykerb evaluation after Chemotherapy (TEACH) study. The Breast. 2007; 16(s1):s47.
  100. Goss PE, Hadji P, Subar M, Abreu P, Thomsen T, Banke-Bochita J. Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women. Breast Cancer Res. 2007; 9(4):R52.
    View in: PubMed
  101. Delea TE, Karnon J, Goss PE. Letter to the Editor: Conclusions regarding relative cost-utility of alternative strategies for use of aromatase inhibitors in postmenopausal women with early breast cancer are premature. Annals of Oncology. 2007; 18(1):197-198, author reply 198-9.
  102. Goss PE. S27 application of aromatase inhibitors in endocrine responsive breast cancers. The Breast. 2007; 16(s1):s8.
  103. Goss PE, Qi S, Hu H, Blanchett D, Langecker P, Lang W. Poster #6096: The effects of atamestane, toremifene or tamoxifen alone or combined on bone, serum lipids and uterus in ovariectomized rats. Poster Presentation 12/17/06 at 29th Annual San Antonio Breast Cancer Symposium, December 14-17, 2006. 2006.
  104. 2006.
  105. Vachon CM, Ingle JN, Suman VJ, Scott CG, Gottardt H, Olson JE, Goss PE. Pilot study of the impact of letrozole vs. placebo on breast density in women completing 5 years of tamoxifen. Breast. 2007 Apr; 16(2):204-10.
    View in: PubMed
  106. Goss PE. Update on the MA.17 extended adjuvant trial. Best Pract Res Clin Endocrinol Metab. 2006; 20 Suppl 1:S5-S13.
  107. Wu M, Goss PE. Reducing the risk of late relapse in postmenopausal women with hormone-sensitive breast cancer - extended adjuvant letrozole. US Oncological Disease 2006, Issue II. 2006; (2):13-16.
  108. Chien AJ, Goss PE. Aromatase inhibitors and bone health in women with breast cancer. J Clin Oncol. 2006 Nov 20; 24(33):5305-12.
    View in: PubMed
  109. Moy B, Goss PE. Lapatinib: current status and future directions in breast cancer. Oncologist. 2006 Nov-Dec; 11(10):1047-57.
    View in: PubMed
  110. Strasser-Weippl K, Goss PE. Strategies for Adjuvant Therapy in Women with Hormone Receptor-Positive Breast Cancer. Translating Advances in Hormonal Therapies for Breast Cancer into Clinical Practice (Monograph). 2006.
  111. 2006.
  112. 2006.
  113. Goss PE, Qi S, Hu H, Cheung AM. The effects of atamestane and toremifene alone and in combination compared with letrozole on bone, serum lipids and the uterus in an ovariectomized rat model. Breast Cancer Res Treat. 2007 Jul; 103(3):293-302.
    View in: PubMed
  114. 2006.
  115. 2006.
  116. Goss PE. Breaking the 5-year barrier: results from the MA.17 extended adjuvant trial in women who have completed adjuvant tamoxifen treatment. European Journal of Cancer Supplements 4(9) - Proceedings of the satellite symposium ’The quiet revolution in breast cancer treatment: how aromatase inhibitors are displacing tamoxifen’. 2006; 4, Issue 9:10-15.
  117. Moy B, Tu D, Pater JL, Ingle JN, Shepherd LE, Whelan TJ, Goss PE. Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer. Ann Oncol. 2006 Nov; 17(11):1637-43.
    View in: PubMed
  118. Whelan TJ, Goss PE, Ingle JN, Tu D, Shepherd L, Pater JL. CORRESPONDENCE: In Reply. J Clin Oncol. 2006; 24(24):4038a-4039.
  119. Tu D, Pater JL, Ingle JN, Goss PE. CORRESPONDENCE- RESPONSE: Re: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive Breast Cancer: Updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2006; 98(16):1162-1163. 2006.
  120. Moy B, Goss PE. Estrogen receptor pathway: resistance to endocrine therapy and new therapeutic approaches. Clin Cancer Res. 2006 Aug 15; 12(16):4790-3.
    View in: PubMed
  121. Delea TE, Karnon J, Goss PE. Conclusions regarding relative cost-utility of alternative strategies for use of aromatase inhibitors in postmenopausal women with early breast cancer are premature. Ann Oncol. 2007 Jan; 18(1):197-8; author reply 198-9.
    View in: PubMed
  122. Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, Shenkier TN, Tozer RG, Palmer MJ, Shepherd LE, Liu S, Tu D, Goss PE. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol. 2006 Aug 1; 24(22):3629-35.
    View in: PubMed
  123. Delea TE, Karnon J, Smith RE, Johnston SRD, Brandman J, Sung JCY, Goss PE. Cost-effectiveness of extended adjuvant letrozole therapy after five years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer. Am J Manag Care. 2006; 12(7):374-386.
  124. Ryan PD, Goss PE. Adjuvant hormonal therapy in peri- and postmenopausal breast cancer. Oncologist. 2006 Jul-Aug; 11(7):718-31.
    View in: PubMed
  125. Ingle J, Tu D, Shepherd L, Palmer M, Pater J, Goss P. Abstract ID #549 - NCIC CTG MA.l7: Intent to treat analysis (ITT) of randomized patients after a medial follow-up of 54 months. Supplement to Journal of Clincial Oncology 24(18S Part I of II): 15S - 2006 ASCO Annual Meeting Proceedings. 2006.
  126. Robert NJ, Goss PE, Ingle JN, Tu D, Shepherd L, Palmer M, Pater J. Abstract ID #550 - Updated analysis of NCIC CTG MA.l7 (letrozole vs. placebo to letrozole vs. placebo) post unblinding. Supplement to Journal of Clincial Oncology 24(18S Part I of II): 15S - 2006 ASCO Annual Meeting Proceedings. 2006.
  127. Moy B, Tu D, Shepherd LE, Pater JL, Whelan TJ, Ingle JN, Goss PE. Abstract ID #6018 - NCIC CTG MA.l7: Tolerability of letrozole among ethnic minority women. Supplement to Journal of Clincial Oncology 24(18S Part I of II): 305S - 2006 ASCO Annual Meeting Proceedings. 2006.
  128. Goss PE, Bondarenko IN, Manikhas GN, Pendergrass KB, Miller WH, Blanchett D, Lang W, Langecker P; for the 777 CLP-29 Study Group. Abstract ID #LBA525 (30375) - Phase 3 study of atamestane + toremifene vs. letrozole in advanced breast cancer. Supplement to Journal of Clincial Oncology 24(18S Part I of II): 9S - 2006 ASCO Annual Meeting Proceedings. 2006.
  129. Moy B, Tu D, Shepherd LE, Pater JL, Whelan TJ, Ingle JN, Goss PE. Poster #6018 NCIC CTG MA.17: Tolerability of letrozole among ethnic minority women (Abstract #9). American Society Of Clinical Oncology Meeting, Atlanta, GA 6/6/06 (Moy Poster & oral presentation). 2006.
  130. Goss PE, Bondarenko IN, Manikhas GN, Pendergrass KB, Miller WH, Blanchett D, Lang W, Langecker P; for the 777 CLP-29 Study Group. Phase 3 study of atamestane + toremifene vs. letrozole in advanced breast cancer [Abstract ID #LBA525 (30375)]. Oral presentation: 2006 ASCO 42nd Annual Meeting, Atlanta, Georgia, June 5, 2006. 2006.
  131. Palmer M, Parulekar W, Bertrim C, Flindall S, Pritchard K, Martino S, Robert N, Muss H, Ingle J, Goss P. Challenges in implementing a study involving re-randomization to an ongoing multinational, intergroup phase III clinical trial. Oral Presentation at 27th Annual Meeting of Society for Clinical Trials, May 21-24, 2006, Orlando, FL; Clinical Trials 2006; 3(Suppl 1):195, abstract 12. 2006.
  132. Goss PE. Preventing relapse beyond 5 years: The MA.17 extended adjuvant trial. Seminars in Oncology -ASCO Investigators' Meeting Supplement(to be published 6/2006). Preventing relapse beyond 5 years: The MA.17 extended adjuvant trial. Seminars in Oncology -ASCO Investigators' Meeting Supplement(to be published 6/2006):TBA Seminars in Oncology -Novartis ASCO Investigators' Meeting Supplement(to be published 6/2006). 2006.
  133. M Palmer, W Parulekar, C Bertrim, S Flindall, K Pritchard, S Martino, N Robert, H Muss, J Ingle, P Goss. Challenges in implementing a study involving re-randomization to an ongoing multinational, intergroup phase III clinical trial. Society for Clinical Trials, 27th Annual Meeting, Orlando, FL (accepted for oral presentation). 2006; abstract submitted 12/1/05.
  134. 2006.
  135. 2006.
  136. Goss PE. Breaking the 5-year barrier: Results from the MA.17 extended adjuvant trial in women who have completed adjuvant tamoxifen treatment. European Journal of Cancer. 2006; 4(Suppl):10-15.
  137. Cigler T, Goss PE. Aromatase inhibitor withdrawal response in metastatic breast cancer. J Clin Oncol. 2006 Apr 20; 24(12):1955-6.
    View in: PubMed
  138. Goss PE. Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial. Semin Oncol. 2006 Apr; 33(2 Suppl 7):S8-12.
    View in: PubMed
  139. 2006.
  140. DQ Meng, JW Chapman, LE Shepherd, W Perulekar, NCIC-CTG, Queen's University-Canada, JN Ingle, PE Goss. Effects of competing causes of death in MA.17, a placebo-controlled trial of letrozole as extended adjuvant therapy for breast cancer patients. ENAR Scientific Program - Contributed Papers: Competing Risks and Cure Rates. 2006.
  141. PE Goss on behalf of the MA.17 Collaborative Trialists. Post-unbinding analysis of NCIC CTG MA.17 (letrozole vs. placebo to letrozole vs. placebo): Updated results. EJC Supplements March 2006:4(2):109, Oral presentation: 5th European Breast Cancer Conference Abstract Book #209, Nice, France March 23,. 2006.
  142. 2006.
  143. PE Goss, J Ingle, and D Tu on behalf of the MA.17 Collaborative Trialists. NCIC CTG MA17: Updated analysis on disease-free survival (DFS) according to estrogen receptor and progesterone receptor status of the primary tumor. EJC Supplements March 2006:4(2):149-150, Poster presentation: 5th European Breast Cancer Conference Abstract Book #350, Nice, France March 23,. 2006.
  144. Ingle JN, Tu D, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Goss PE. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Res Treat. 2006 Oct; 99(3):295-300.
    View in: PubMed
  145. 2006.
  146. Goss, PE. Overview of bone health data from the aromatase inhibitor trials. The American Journal of Oncology Review (CME Journal Supplement). 2006; 5(Supplement 1)(3):12-19.
  147. Goss PE, Chlebowski RT, LeBoff MS, Cosman F, Singer FR, Sledge GW. Recommendations on bone health management for women with early stage breast cancer. The American Journal of Oncology Review (CME Journal Supplement). 2006; 5(Supplement 1)(3):34-43.
  148. 2006.
  149. 2006.
  150. Pritchard KI, Goss PE, Shepherd L. The extended adjuvant NCIC CTG MA.17 trials: initial and rerandomization studies. Breast. 2006 Feb; 15 Suppl 1:S14-20.
    View in: PubMed
  151. 2006.
  152. 2006.
  153. 2006.
  154. D Meng, J-A Chapman, L Shepherd, W Parulekar, J Ingle, P Goss, D Li. Competing causes of death in MA.17, a placebo-controlled trial of letrozole as extended adjuvant therapy for breast cancer patients. Queen's University Cancer Research Institute Retreat (Poster Presentation). 2006; (accepted for poster presentat.
  155. Karnon J, Delea T, Johnston SR, Smith R, Brandman J, Sung J, Goss PE. Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy: the UK perspective. Pharmacoeconomics. 2006; 24(3):237-50.
    View in: PubMed
  156. D Meng, J-A Chapman, L Shepherd, W Parulekar, J Ingle, P Goss . Competing causes of death in MA.17, a placebo-controlled trial of letrozole as extended adjuvant therapy for breast cancer patients. Eastern North American Region (ENAR) of the Biometrics Society, 2006 Spring Meeting. 2006; abstract submission 11/15/05.
  157. Vachon CM, Ingle JN, Scott CG, Olson JE, Goss PE. Pilot study of changes in mammographic density in women treated with letrozole or placebo on NCIC CTG MA17 (Abstract #6005). Breast Cancer Research and Treatment 2005:94(Suppl 1):S249; 28th Annual San Antonio Breast Cancer Symposium. 2005; San Antonio, TX.
  158. Goss PE, Ingle JN, Tu D on behalf of the MA17 Collaborative Trialists. NCIC CTG MA17: disease free survival according to estrogen receptor and progesterone receptor status of the primary tumor (Abstract #2042). Breast Cancer Research and Treatment 2005:94(Suppl 1):S98; 28th Annual San Antonio Breast Cancer Symposium. 2005; San Antonio, TX.
  159. Goss PE, Qi S, Hu H, Cheung AM, Lang W, Blanchett DG, Langecker PJ. The effects of atamestane and toremifene alone or combined on bone, serum lipids and uterus, comparing them to letrozole in the ovariectomized rat (Abstract #2046). Breast Cancer Research and Treatment 2005:94(Suppl 1):S99-S100; 28th Annual San Antonio Breast Cancer Symposium. 2005; San Antonio, TX.
  160. Chapman JW, Jasani B, Ibrahim M, Miller K, Murray D, Hewlett B, Daidone MG, Allred C, Hammond E, Li D, Sweep F, O'Malley FP, Kelly J, Goss P. Standardization of estrogen and progesterone receptor assay values (Abstract #5101). Breast Cancer Research and Treatment 2005; 94(Suppl 1):S242; 28th Annual San Antonio Breast Cancer Symposium. 2005.
  161. Ingle JN, Goss PE, Tu D on behalf of the MA17 Trialists. Analysis of duration of letrozole extended adjuvant therapy as measured by hazard ratios of disease recurrence over time for patients on NCIC CTG MA.17 (Abstract #17 -Oral presentation 12/9/05). Breast Cancer Research and Treatment 2005:9(Suppl 1):S11; 28th Annual San Antonio Breast Cancer Symposium. 2005; San Antonio, TX.
  162. Goss PE, Ingle JN, Palmer MJ, Shepherd LE, Tu D on behalf of the MA17 Collaborative Trialists. Updated analysis of NCIC CTG MA.17 (letrozole vs. placebo to letrozole vs placebo) post unblinding (Abstract #16 - Oral presentation 12/9/05). Breast Cancer Research and Treatment 2005:94(Suppl 1):S10-S11; 28th Annual San Antonio Breast Cancer Symposium. 2005; San Antonio, TX.
  163. Cheung AM, Tomlinson G, Goss PE. Bone loss with exemestane: Is the jury still out? J Clin Oncol. 2005 Dec 20; 23(36):9433-4; author reply 9433-5.
    View in: PubMed
  164. 2005.
  165. Strasser-Weippl K & Goss PE. Endocrine therapy of breast cancer. Breast Cancer in Women of African Descent. Williams CKO, Olopade O, Falkson C, eds. 2005; Chapter 9:221-248.
  166. Ryan PD, Goss PE. The evolving role of aromatase inhibitors in the treatment of early-stage breast cancer. Nat Clin Pract Oncol. 2005 Dec; 2(12):596-7.
    View in: PubMed
  167. Strasser-Weippl K., Goss PE. Adjuvant endocrine therapy options in hormone-dependent breast cancer. IN: Endocrine treatment for breast cancer - How best to integrate new results in clinical practice?. EJC Supplements October 2005; 3(3): 247-254, ECCO 13 - the European Cancer Conference Education Book. 2005.
  168. 2005.
  169. Chapman JW, Jasani B, Ibrahim M, Miller K, Murray D, Hewlett B, Daidone MG, Allred C, Hammond E, Li D, Sweep F, O'Malley FP, Kelly J, Goss PE. Standardization of Estrogen and Progesterone Receptor Assay Values. Breast Cancer Res Treat. 2005; 94(S1):S242.
  170. Maunsell E, Laval U, Au H-J, Palmer MJ, Tu D, Whelan TJ, Goss PE, Davis A. Health-related quality of life in breast cancer survivors after 5 years of adjuvant tamoxifen (Abstract #1221). Qual Life Res 2005; 14(9):2092. 2005.
  171. Whelan TJ, Goss PE, Ingle JN, Pater JL, Tu D, Pritchard K, Liu S, Shepherd LE, Palmer M, Robert NJ, Martino S, Muss HB. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol. 2005 Oct 1; 23(28):6931-40.
    View in: PubMed
  172. 2005.
  173. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurliamann B, Senn HJ, and Panel Members. Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005. Annals of Oncology. 2005; 16(10):1569-1583.
  174. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005 Sep 7; 97(17):1262-71.
    View in: PubMed
  175. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ & Panel Members. Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005. Annals of Onc. 2005; 16(10):1569-83.
  176. Ingle J, Goss PE and Tu, D on behalf of the MA.17 Collaborative Trialists. NCIC CTG MA.17: Increasing benefit of letrozole with longer duration of treatment as measured by the hazard ratio of disease recurrence over time. EJC Supplements October 2005:3(2):74, Oral presentation: 13th European Cancer Conference, Abstract Book #266, Paris, France October 31,. 2005.
  177. Goss PE, Ingle J, and Tu, D on behalf of the MA.17 Collaborative Trialists. NCIC CTG MA.17: Disease-free survival according to estrogen receptor and progesterone receptor status of the primary tumor. EJC Supplements October 2005:3(2):74-75, Oral presentation: 13th European Cancer Conference, Abstract Book #267, Paris, France October 31,. 2005.
  178. Chabner BA, Amrein PC, Druker BJ, Michaelson MD, Mitsiades CS, Goss PE, Ryan DP, Ramachandra S, Richardson PG, Supko JG, Wilson WH. Antineoplastic Agents. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th Edition. Brunton LL, Lazo JS, Parker KL (eds). 2005; Section IX:Chapter 51, 1315-1403.
  179. Luk C, Goss PE, Pritchard K, Whelan TJ, Liu S, Shepherd L, Pater J. Determinants of preferences for starting extended adjuvant letrozole in postmenopausal women following five years of tamoxifen. Proc Annu Meet Am Soc Clin Oncol. 2005; A642.
  180. Goss PE, Qi S, Hu H, Cheung AM, Lang W, Blanchett DG, Langecker PJ. The effects of atamestane, toremifene, and atamestane plus toremifene compared to letrozole on bone, serum lipids and uterus. Proc Ann Meet Am Soc Clin Oncol. 2005; A600.
  181. Thompson LU, Chen JM, Li T, Strasser-Weippl K, Goss PE. Dietary flaxseed alters tumor biological markers in postmenopausal breast cancer. Clin Cancer Res. 2005 May 15; 11(10):3828-35.
    View in: PubMed
  182. Pater J, Goss P, Ingle J, Shelley W, Shepherd L. The ethics of early stopping rules. J Clin Oncol. 2005 Apr 20; 23(12):2862-3; author reply 2863-4.
    View in: PubMed
  183. Wasan KM, Goss PE, Pritchard PH, Shepherd L, Palmer MJ, Liu S, Tu D, Ingle JN, Heath M, Deangelis D, Perez EA. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Ann Oncol. 2005 May; 16(5):707-15.
    View in: PubMed
  184. 2005.
  185. Strasser-Weippl K, Goss PE. Advances in adjuvant hormonal therapy for postmenopausal women. J Clin Oncol. 2005 Mar 10; 23(8):1751-9.
    View in: PubMed
  186. Suen TC, Tang MS, Goss PE. Model of transcriptional regulation of the BRCA1-NBR2 bi-directional transcriptional unit. Biochim Biophys Acta. 2005 May 1; 1728(3):126-34.
    View in: PubMed
  187. Strasser-Weippl K, Goss PE. Counteracting estrogen as breast cancer prevention. (Chapter 19). Cancer Chemoprevention: Vol. 2 -Strategies for Cancer Chemoprevention. Kelloff GJ, Hawk ET, Sigman CC (eds). 2005; 2(Chapter 19):249-264.
  188. Strasser-Weippl K, Goss PE. Prospects for preinvasive breast cancer and prevention. Aromatase inhibitors for the treatment of breast cancer. Ellis MJ, ed. 2005; 127-142.
  189. Goss PE. Endocrine treatment beyond 5 years. The Breast: Primary Therapy of Early Breast Cancer. 2005; 14(Suppl 1):S3, S5.
  190. Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, Shenkier TN, Tozer RG, Palmer MJ, Shepherd LE, Tu D, Goss PE. Effect of letrozole versus placebo on bone mineral density in women completing greater than or egual to 5 years of adjuvant tamoxifen: NCIC CTG MA.17b. Breast Cancer Research and Treatment, Vol 88, Supplement 1, 2004: S36:Abstract #404. Presented at 27th Annual SABCS, San Antonio, TX, December 8,. 2004.
  191. 2004.
  192. 2004.
  193. 2004.
  194. Goss PE. Changing clinical practice: extending the benefits of adjuvant endocrine therapy in breast cancer. Semin Oncol. 2004 Dec; 31(6 Suppl 12):15-22.
    View in: PubMed
  195. 2004.
  196. 2004.
  197. 2004.
  198. 2004.
  199. Goss PE, Qi S, Cheung AM, Hu H, Mendes M, Pritzker KP. The selective estrogen receptor modulator SCH 57068 prevents bone loss, reduces serum cholesterol and blocks estrogen-induced uterine hypertrophy in ovariectomized rats. J Steroid Biochem Mol Biol. 2004 Sep; 92(1-2):79-87.
    View in: PubMed
  200. Goss PE, Qi S, Cheung AM, Hu H, Mendes M, Pritzker KP. Effects of the steroidal aromatase inhibitor exemestane and the nonsteroidal aromatase inhibitor letrozole on bone and lipid metabolism in ovariectomized rats. Clin Cancer Res. 2004 Sep 1; 10(17):5717-23.
    View in: PubMed
  201. Karnon J, Johnston SRD, Delea T, Smith R, Brandman J, Sung J, Goss PE. Cost-effectiveness of extended adjuvant letrozole after five years of tamoxifen in postmenopausal early breast cancer. Proc Annu Meet Am Soc Clin Oncol. 2004; 23:528, A6044.
  202. Subar M, Goss PE, Thomsen T, Banke-Bochita J. Effects of steroidal and nonsteroidal aromatase inhibitors (AIs) on markers of bone turnover and lipid metabolism in healthy volunteers. Proc Annu Meet Am Soc Clin Oncol. 2004; 23:734, A8038.
  203. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pater JL. Updated analysis of the NCIC CTG MA.17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal women with early stage breast cancer. Proc Annu Meet Am Soc Clin Oncol. 2004; 23:87, A847.
  204. Whelan T, Goss PE, Ingle JN, Pater JL, Shepherd LE, Palmer M, Tu D, Robert NJ, Martino S, Muss HB. Assessment of quality of life (QOL) in MA.17, a randomized placebo-controlled trial of letrozole in postmenopausal women following five years of tamoxifen. Proc Annu Meet Am Soc Clin Oncol. 2004; 23:6, A517.
  205. 2004.
  206. Arun B, Goss P. The role of COX-2 inhibition in breast cancer treatment and prevention. Semin Oncol. 2004 Apr; 31(2 Suppl 7):22-9.
    View in: PubMed
  207. Goss PE, Strasser-Weippl K. Aromatase inhibitors for chemoprevention. Best Pract Res Clin Endocrinol Metab. 2004 Mar; 18(1):113-30.
    View in: PubMed
  208. Goss PE, Qi S, Josse RG, Pritzker KP, Mendes M, Hu H, Waldman SD, Grynpas MD. The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats. Bone. 2004 Mar; 34(3):384-92.
    View in: PubMed
  209. Buzdar AU, Hietanen P, Makela M, Shahab N, Harris SR, Hellman S, Hellman D, Goss PE, Ingle JN, Pater JL, Bryant J, Wolmark N, Burstein HJ. Letrozole in breast cancer. N Engl J Med. 2004; 350(7):727-30.
  210. 2004.
  211. 2004.
  212. Goss PE. Aromatase inhibitors in the treatment and prevention of breast cancer. Proc FGOG. 2004; 66.
  213. Goss PE. New Roles for Aromatase Inhibitors. Breast Cancer Res Treat. 2004.
  214. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early stage breast cancer. Breast Diseases: A Yearbook Quarterly. S. Eva Singletary, MD ed. 2004.
  215. Goss PE. Introduction. Semin Oncol. 2004; 31(6 Suppl 12):1-2.
  216. Come SE, Buzdar AU, Arteaga CL, Bissell MJ, Brown MA, Ellis MJ, Goss PE, Green JE, Ingle JN, Lee AV, Medina D, Nicholson RI, Santen RJ, Schiff R, Hart CS. Proceedings of the Third International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement. Clin Cancer Res. 2004 Jan 1; 10(1 Pt 2):327S-330S.
    View in: PubMed
  217. Goss PE. Targeting estrogen synthesis: a rational approach to preventing breast cancer. Cancer Prevention. 2004; 3:6.
  218. Goss PE, Strasser-Weippl K. Prevention strategies with aromatase inhibitors. Clin Cancer Res. 2004 Jan 1; 10(1 Pt 2):372S-9S.
    View in: PubMed
  219. Tchen N, Juffs HG, Downie FP, Yi QL, Hu H, Chemerynsky I, Clemons M, Crump M, Goss PE, Warr D, Tweedale ME, Tannock IF. Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol. 2003 Nov 15; 21(22):4175-83.
    View in: PubMed
  220. 2003.
  221. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003 Nov 6; 349(19):1793-802.
    View in: PubMed
  222. Wang P, Branch DR, Bali M, Schultz GA, Goss PE, Jin T. The POU homeodomain protein OCT3 as a potential transcriptional activator for fibroblast growth factor-4 (FGF-4) in human breast cancer cells. Biochem J. 2003 Oct 1; 375(Pt 1):199-205.
    View in: PubMed
  223. Clemons M, Hamilton T, Mansi J, Lockwood G, Goss P. Management of recurrent locoregional breast cancer: oncologist survey. Breast. 2003 Oct; 12(5):328-37.
    View in: PubMed
  224. Goss PE. Breast cancer prevention--clinical trials strategies involving aromatase inhibitors. J Steroid Biochem Mol Biol. 2003 Sep; 86(3-5):487-93.
    View in: PubMed
  225. Goss PE. Emerging role of aromatase inhibitors in the adjuvant setting. Am J Clin Oncol. 2003 Aug; 26(4):S27-33.
    View in: PubMed
  226. 2003.
  227. 2003.
  228. 2003.
  229. CME audio and print monograph and activity: Breast Cancer Update, Conversations with Oncology Leaders, Bridging the Gap between Research and Patient Care. Endocrine pathways of breast cancer carcinogenesis De novo vs. acquired resistance to endocrine therapy. Clinical implications of acquired resistance to aromatase inhibitors. 2003.
  230. 2003.
  231. 2003.
  232. 2003.
  233. Owens BM, Zhu YX, Suen TC, Wang PX, Greenblatt JF, Goss PE, Hawley RG. Specific homeodomain-DNA interactions are required for HOX11-mediated transformation. Blood. 2003 Jun 15; 101(12):4966-74.
    View in: PubMed
  234. 2003.
  235. 2003.
  236. Langecker P, Lang W, Blanchett D, Bailey P, Scribner C, Goss PE. Combined hormonal therapy for advanced breast cancer in postmenopausal patients. Breast Cancer Res. 2003; 5(Suppl 1):S18, A62.
  237. Goss PE & Strasser-Weippl K. Estrogen antagonism as chemoprevention of breast cancer. Anti-Aromatase Therapy in Breast Cancer. Sasano H, Toi M, eds. 2003; 193-226.
  238. Goss PE. Introduction: reviewing the current status of aromatase inhibitors. Curr Oncol. 2003; 10(Suppl 1):s2-s3.
  239. Goss PE. The evolving role of aromatase inhibitors in the adjuvant breast cancer setting. Am J Cancer. 2003; 2(Suppl 1):13-18.
  240. Goss PE. Potential preventive role of aromatase inhibitors for patients at risk for breast cancer. Curr Oncol. 2003; 10 (Suppl 1):s25-s29.
  241. Monograph (accredited program for physicians) . The effects of anti-aromatase on bone. 2003.
  242. Goss PE, Thomsen T, Banke-Bochita J, Hadji P. Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover and lipid metabolism in healthy volunteers. Breast Cancer Res Treat. 2003; 82(Suppl 1):S101, A427.
  243. Strassmer-Weippl K, Goss PE. Prevention of breast cancer using SERMs and aromatase inhibitors. J Mammary Gland Biol Neoplasia. 2003 Jan; 8(1):5-18.
    View in: PubMed
  244. Goss PE & Strasser-Weippl K. Aromatase inhibitors for chemoprevention. Managing Breast Cancer Risk. Morrow M, Jordan VC, eds. 2003; 199-213.
  245. 2002.
  246. 2002.
  247. 2002.
  248. 2002.
  249. Goss PE, Smith RE. Letrozole for the management of breast cancer. Expert Rev Anticancer Ther. 2002 Jun; 2(3):249-60.
    View in: PubMed
  250. 2002.
  251. 2002.
  252. 2002.
  253. 2002.
  254. Interviews from the American Society of Clinical Oncology 38th Annual Meeting and Review of Current Literature. Physicians Audio News. Expanding the use of anti-aromatase agents. 2002.
  255. Tchen N, Juffs H, Yi QL, Downie F, Crump M, Goss PE, Warr D, Tannock IF. Fatigue, menopausal symptoms and their interaction in 100 women receiving adjuvant chemotherapy for breast cancer and 100 age-matched controls: results of a prospective cohort stu. Proc Annu Meet Am Soc Clin Oncol. 2002; 21(Part 1:388a):A1548.
  256. 2002.
  257. 2002.
  258. 2002.
  259. Goss P. Anti-aromatase agents in the treatment and prevention of breast cancer. Cancer Control. 2002 Mar-Apr; 9(2 Suppl):2-8.
    View in: PubMed
  260. Tannock I, Tchen N, Juffs H, Downie F, Chemerynsky I, Yi QL, Hu H, Crump M, Goss PE, Warr D. Fatigue, menopausal symptoms and cognitive dysfunction associated with adjuvant chemotherapy: results of a large prospective controlled study. Breast Cancer Res Treat. 2002; 76(Suppl 1):S138, A549.
  261. Goss PE, Strasser K. Tamoxifen resistant and refractory breast cancer: the value of aromatase inhibitors. Drugs. 2002; 62(6):957-66.
    View in: PubMed
  262. Goss PE, Cheung AM, Lowery C, Hu H, Qi S. Comparison of the effects of exemestane, 17-hydroexemestane and letrozole on bone and lipid metabolism in the ovariectomized rat. Breast Cancer Res Treat. 2002; 76(Suppl 1):S107, A415.
  263. Goss PE, Grynpas MD, Josse R, Lowery C, Qi S, Hu H. The steroidal aromatase inactivator exemestane prevents bone loss and reduces serum cholesterol in ovariectomized rats. The North American Menopause Society 13th Annual Meeting. 2002; 76:A25.
  264. Goss PE, Cheung A, Pachter J, Hu H, Qi S. The selective estrogen receptor modulator SCH 57068 prevents bone loss, reduces serum cholesterol and blocks estrogen-induced uterine hypertrophy in ovariectomized rats. The North American Menopause Society 13th Annual Meeting. 2002; 76:A26.
  265. Goss PE. Aromatase inhibitors and early breast cancer. Endocrine Therapy in Breast Cancer. Miller WR, Ingle JN, eds. 2002; 135-44.
  266. Goss PE, Cheung AM, Pachter J, Hu H, Qi S. The selective estrogen receptor modulator SCH 57068 prevents bone loss, reduces serum cholesterol and blocks estrogen-induced uterine hypertrophy in the ovariectomized rat. Breast Cancer Res Treat. 2002; 76(Suppl 1):S108, A418.
  267. Goss PE, Cheung A, Pachter J, Hu H, Qi S. The new antiestrogen SCH57068 prevents bone loss, reduces serum cholesterol and blocks estrogen induced uterine hypertrophy in ovariectomized rats. 2002; 21(Part 1):118a, A470.
  268. Goss PE. Aromatase inhibitors and chemoprevention of breast cancer. Endocrine Therapy in Breast Cancer. Miller WR, Ingle JN, eds. 2002; 309-18.
  269. Interviews from the 24th Annual San Antonio Breast Cancer Symposium and Review of Current Literature. Physicians Audio News. Clinical Findings: update 2002 breast cancer treatment using epirubicin and exemestane. 2001.
  270. 2001.
  271. Goss PE. Preliminary data from ongoing adjuvant aromatase inhibitor trials. Clin Cancer Res. 2001 Dec; 7(12 Suppl):4397s-4401s; discussion 4411s-4412s.
    View in: PubMed
  272. Goss PE, Strasser K. Chemoprevention with aromatase inhibitors--trial strategies. J Steroid Biochem Mol Biol. 2001 Dec; 79(1-5):143-9.
    View in: PubMed
  273. Buzdar AU, Come SE, Brodie A, Ellis M, Goss PE, Ingle JN, Johnston SR, Lee AV, Osborne CK, Vogel VG, Hart CS. Proceedings of the First International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: summary consensus statement. Clin Cancer Res. 2001 Dec; 7(12 Suppl):4335s-4337s; discussion 4411s-4412s.
    View in: PubMed
  274. 2001.
  275. Canil CM, Markin G, Cappuis P, Goshen R, Meschino W, Goss PE, Narod S, Foulkes W, Warner E. Comparison of clinical, radiological, and pathological features in age-matched Ashkenazi Jewish (AJ) women with breast cancer with and without BRCA-1 and BRCA-2 mutations. Proc Annu Meet Am Soc Clin Oncol. 2001; 20(413a):A1649.
  276. 2001.
  277. Clemons M, Hamilton T, Goss P. Does treatment at the time of locoregional failure of breast cancer alter prognosis? Cancer Treat Rev. 2001 Apr; 27(2):83-97.
    View in: PubMed
  278. Clemons M, Danson S, Hamilton T, Goss P. Locoregionally recurrent breast cancer: incidence, risk factors and survival. Cancer Treat Rev. 2001 Apr; 27(2):67-82.
    View in: PubMed
  279. 2001.
  280. 2001.
  281. Goss PE, Strasser K. Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol. 2001 Feb 1; 19(3):881-94.
    View in: PubMed
  282. Suen TC, Goss PE. Identification of a novel transcriptional repressor element located in the first intron of the human BRCA1 gene. Oncogene. 2001 Jan 25; 20(4):440-50.
    View in: PubMed
  283. Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med. 2001 Jan 25; 344(4):276-85.
    View in: PubMed
  284. Goss PE & Reid C. Aromatase Inhibitors. Endocrine Therapy for Breast and Prostate Cancer. Jordan VC, Furr BJA, eds. 2001; 235-63.
  285. Goss PE, Thompson LU. The effects of dietary flaxseed on mammographic density. Breast Cancer Res Treat. 2001; 69(3):223, A125.
  286. Goss PE & Strasser K. Chemoprevention with Aromatase Inhibitors. Aromatase Inhibition in Breast Cancer. Miller WR, Santen RJ, eds. 2001; 161-81.
  287. Goss PE & Strasser K. Chemoprevention of Breast Cancer. Manual of Breast Diseases. Jatoi I, ed. 2001; 481-503.
  288. Members of the Ad Hoc Raloxifene in Breast Cancer Group: Zeenat HA, Burnell M, Blackstein M, Colwell B, Dent S, Gelmon K, Goss PE, Laing K, Levine M, Lickley L, Pritchard K, Robidoux A, Vandenberg T, Verma S, Walley B. Raloxifene: handle with care. CMAJ. 2001; 165(2):151-53.
  289. Goss PE, Yow O. An overview of aromatase inhibitors in the treatment of metastatic breast cancer. Curr Oncol. 2001; 8(2):95-103.
  290. Goss PE, Grynpas M, Qi S, Hu H. The effects of exemestane on bone and lipids in the ovariectomized rat. Breast Cancer Res Treat. 2001; 69(3):224, A132.
  291. 2000.
  292. Jiang Z, Liang P, Leng R, Guo Z, Liu Y, Liu X, Bubnic S, Keating A, Murray D, Goss P, Zacksenhaus E. E2F1 and p53 are dispensable, whereas p21(Waf1/Cip1) cooperates with Rb to restrict endoreduplication and apoptosis during skeletal myogenesis. Dev Biol. 2000 Nov 1; 227(1):8-41.
    View in: PubMed
  293. Goss PE, Strasser K, Marques R, Clemons M, Oza A, Goel R, Blackstein M, Kaizer L, Sterns EE, Nabholtz JM, De Coster R, Crump M, Abdolell M, Qi S. Liarozole fumarate (R85246): in the treatment of ER negative, tamoxifen refractory or chemotherapy resistant postmenopausal metastatic breast cancer. Breast Cancer Res Treat. 2000 Nov; 64(2):177-88.
    View in: PubMed
  294. Chan A, Pintilie M, Vallis K, Girourd C, Goss P. Breast cancer in women < or = 35 years: review of 1002 cases from a single institution. Ann Oncol. 2000 Oct; 11(10):1255-62.
    View in: PubMed
  295. Clemons M, Loijens L, Goss P. Breast cancer risk following irradiation for Hodgkin's disease. Cancer Treat Rev. 2000 Aug; 26(4):291-302.
    View in: PubMed
  296. Jin T, Zhang X, Li H, Goss PE. Characterization of a novel silencer element in the human aromatase gene PII promoter. Breast Cancer Res Treat. 2000 Jul; 62(2):151-9.
    View in: PubMed
  297. Cohen L, Hack TF, de Moor C, Katz J, Goss PE. The effects of type of surgery and time on psychological adjustment in women after breast cancer treatment. Ann Surg Oncol. 2000 Jul; 7(6):427-34.
    View in: PubMed
  298. Patnaik A, MacKinnon J, Goss P, Nagy T, Stewart K, Keating A, Crump M. Phase I/II trial of cyclophosphamide, mitoxantrone, and escalated doses of carboplatin supported by peripheral-blood stem cells in women with metastatic breast cancer. J Clin Oncol. 2000 Jun; 18(12):2363-8.
    View in: PubMed
  299. Norris B, Pritchard KI, James K, Myles J, Bennett K, Marlin S, Skillings J, Findlay B, Vandenberg T, Goss P, Latreille J, Rudinskas L, Lofters W, Trudeau M, Osoba D, Rodgers A. Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8. J Clin Oncol. 2000 Jun; 18(12):2385-94.
    View in: PubMed
  300. 2000.
  301. 2000.
  302. Strasser K, Goss PE, Tye L, Qi S, Abdolell M, Marques R, De Coster R, Bruynseels J, Wadden N, Crump M, Kirkbride P, Fyles A, Clemons MJ. Effects of liarozole fumarate (R85246) in combination with tamoxifen. Proc Annu Meet Am Soc Clin Oncol. 2000; 19:A391.
  303. 2000.
  304. 2000.
  305. Suen TC, Goss PE. Characterization of a repressor element and a juxtaposed tissue-restricted activator element located on the distal neu gene promoter. J Biol Chem. 2000 Mar 3; 275(9):6600-7.
    View in: PubMed
  306. Abraham R, Nagy T, Goss PE, Crump M. High dose chemotherapy and autologous blood stem cell support in women with breast carcinoma and isolated supraclavicular lymph node metastases. Cancer. 2000 Feb 15; 88(4):790-5.
    View in: PubMed
  307. Rapley EA, Crockford GP, Teare D, Biggs P, Seal S, Barfoot R, Edwards S, Hamoudi R, Heimdal K, Fossâ SD, Tucker K, Donald J, Collins F, Friedlander M, Hogg D, Goss P, Heidenreich A, Ormiston W, Daly PA, Forman D, Oliver TD, Leahy M, Huddart R, Cooper CS, Bodmer JG, Easton DF, Stratton MR, Bishop DT. Localization to Xq27 of a susceptibility gene for testicular germ-cell tumours. Nat Genet. 2000 Feb; 24(2):197-200.
    View in: PubMed
  308. Goss PE, Oza A, Goel R, Nabholtz JM, De Coster R, Bruynseels J, Reid C, Wadden N, Crump M, Tye LM. Liarozole fumarate (R85246): a novel imidazole in the treatment of receptor positive postmenopausal metastatic breast cancer. Breast Cancer Res Treat. 2000 Jan; 59(1):55-68.
    View in: PubMed
  309. Suen TC, Goss PE. Identification of a novel transcriptional repressor element located in the first intron of the human BRCA1 gene. Abstracts of the Cold Spring Harbor Symposium on Cancer Genetics and Tumor Suppressor Genes. 2000; 200.
  310. Goss PE, Li T, Theriault M, Pinto S, Thompson LU. Effects of dietary flaxseed in women with cyclical mastalgia. Breast Cancer Res Treat. 2000; 64(1):49, A153.
  311. Clemons M, Hamilton T, Mansi J, Steinman M, Lockwood G, Goss PE. Management of recurrent locoregional breast cancer (BC): oncologist consensus survey. Ann Oncol. 2000; 11(Suppl 4):98PD.
  312. Thompson LU, Li T, Chen J, Goss PE. Biological effects of dietary flaxseed in patients with breast cancer. Breast Cancer Res Treat. 2000; 64(1):50, A157.
  313. Madarnas Y, Franssen E, Sawka CA, Pintilie M, Goss PE. Patterns of body size in male breast cancer and impact of obesity on disease outcome. The Toronto experience. Breast Cancer Res Treat. 2000; 64(1):127, A547.
  314. Blackstein M, Fyles A, Goss PE, Olsson S. The role of aromatase inhibitors in breast cancer: a discussion. Curr Oncol. 2000; 6(4):211-6.
  315. Foulkes WD, Brunet JS, Warner E, Goodwin PJ, Meschino W, Narod SA, Goss PE, Glendon G. The importance of a family history of breast cancer in predicting the presence of a BRCA mutation. Am J Hum Genet. 1999 Dec; 65(6):1776-9.
    View in: PubMed
  316. Suen TC, Goss PE. Transcription of BRCA1 is dependent on the formation of a specific protein-DNA complex on the minimal BRCA1 Bi-directional promoter. J Biol Chem. 1999 Oct 29; 274(44):31297-304.
    View in: PubMed
  317. 1999.
  318. Gervais-Fagnou DD, Girouard C, Laperriere N, Pintillie M, Goss PE. Breast cancer in women following supradiaphragmatic irradiation for Hodgkin's disease. Oncology. 1999 Oct; 57(3):224-31.
    View in: PubMed
  319. 1999.
  320. 1999.
  321. Warner E, Foulkes W, Goodwin P, Meschino W, Blondal J, Paterson C, Ozcelik H, Goss P, Allingham-Hawkins D, Hamel N, Di Prospero L, Contiga V, Serruya C, Klein M, Moslehi R, Honeyford J, Liede A, Glendon G, Brunet JS, Narod S. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst. 1999 Jul 21; 91(14):1241-7.
    View in: PubMed
  322. Goss P, Stewart AK, Couture F, Klasa R, Glück S, Kaizer L, Burkes R, Charpentier D, Palmer M, Tye L, Dulude H. Combined results of two phase II studies of Taxol (paclitaxel) in patients with relapsed or refractory lymphomas. Leuk Lymphoma. 1999 Jul; 34(3-4):295-304.
    View in: PubMed
  323. 1999.
  324. 1999.
  325. 1999.
  326. Goss PE. Risks versus benefits in the clinical application of aromatase inhibitors. Endocr Relat Cancer. 1999 Jun; 6(2):325-32.
    View in: PubMed
  327. Peng HQ, Liu L, Goss PE, Bailey D, Hogg D. Chromosomal deletions occur in restricted regions of 5q in testicular germ cell cancer. Oncogene. 1999 May 27; 18(21):3277-83.
    View in: PubMed
  328. 1999.
  329. Califaretti N, Davidson M, Goss PE, Crump M. Is there a role for GCSF with adjuvant CEF chemotherapy for breast cancer (BC)?. Proc Annu Meet Am Soc Clin Oncol. 1999; 18:A336.
  330. 1999.
  331. 1999.
  332. 1999.
  333. 1999.
  334. Jin T, Wang P, Qi S, Branch DR, Goss PE. The embryonic transcription factor OCT3 is selectively expressed in human breast cancer cells and its expression is down-regulated by retinoic acid. Proc Am Assoc Cancer Res. 1999; 40:A4853.
  335. 1999.
  336. Jin T, Branch DR, Zhang X, Qi S, Youngson B, Goss PE. Examination of POU homeobox gene expression in human breast cancer cells. Int J Cancer. 1999 Mar 31; 81(1):104-12.
    View in: PubMed
  337. Goss PE, Reid C, Pintilie M, Lim R, Miller N. Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955-1996. Cancer. 1999 Feb 1; 85(3):629-39.
    View in: PubMed
  338. Goss PE, Winer EP, Tannock IF, Schwartz LH. Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group. J Clin Oncol. 1999 Jan; 17(1):52-63.
    View in: PubMed
  339. Goss PE, Walde D, De Coster R, Langenaeken C, Bruynseels J. Rivizor--a new third-generation aromatase inhibitor for the treatment of advanced breast cancer after tamoxifen failure. Oncology. 1999; 56(2):114-21.
    View in: PubMed
  340. Hack TF, Cohen L, Katz J, Robson LS, Goss P. Physical and psychological morbidity after axillary lymph node dissection for breast cancer. J Clin Oncol. 1999 Jan; 17(1):143-9.
    View in: PubMed
  341. Goss PE. Aromatase inhibitors in the treatment and prevention of breast cancer. Curr Oncol. 1999; 6(3):138-43.
  342. Clemons MJ, Tye LM, Marques R, Brennan J, Reid C, Kirkbride P, Fyles A, Young SD, Hayes AL, Crump M, Goss PE. Phase I/II dose–escalation study of liarozole (R85246) plus tamoxifen in postmenopausal women with metastatic breast cancer. Breast Cancer Res Treat. 1999; 57(1):106, A434.
  343. 1998.
  344. 1998.
  345. Dawson LA, Chow E, Goss PE. Evolving perspectives in contralateral breast cancer. Eur J Cancer. 1998 Dec; 34(13):2000-9.
    View in: PubMed
  346. 1998.
  347. 1998.
  348. 1998.
  349. 1998.
  350. 1998.
  351. 1998.
  352. 1998.
  353. 1998.
  354. 1998.
  355. Warner E, Hedley D, Andrulis I, Myers R, Trudeau M, Warr D, Pritchard KI, Blackstein M, Goss PE, Franssen E, Roche K, Knight S, Webster S, Fraser RA, Oldfield S, Hill W, Kates R. Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen. Clin Cancer Res. 1998 Jun; 4(6):1451-7.
    View in: PubMed
  356. Crump M, Abraham R, MacKinnon J, Nagy T, Roitman D, Goss PE. High dose chemotherapy and stem cell support (SCT) in women with breast cancer and isolated supraclavicular node metastases. Proc Annu Meet Am Soc Clin Oncol. 1998; 17:A311.
  357. Jin T, Qi S, Branch D, Youngson B, Goss PE. The embryonic transcription factor OCT3 is expressed by human primary breast cancer cells and by NMU induced mammary gland tumors in rats. Proc Annu Meet Am Soc Clin Oncol. 1998; 17:A2182.
  358. Abraham R, Crump M, MacKinnon J, Nagy K, Arts K, Goss PE, Roitman D, Stewart AK, Keating A. Alteration in cardiac function following high dose chemotherapy for breast cancer. Proc Annu Meet Am Soc Clin Oncol. 1998; 17:A336.
  359. 1998.
  360. 1998.
  361. 1998.
  362. 1998.
  363. 1998.
  364. 1998.
  365. 1998.
  366. Goss PE, Sierra S. Current perspectives on radiation-induced breast cancer. J Clin Oncol. 1998 Jan; 16(1):338-47.
    View in: PubMed
  367. Participant. Boar’s Head Workshop Conference. J Clin Endocr Metab. 1998; 83(6):1993-2000.
  368. Goss PE. Biological characteristics of breast cancer in women who develop breast cancer while receiving HRT. Obstet Gyneco Surv. 1998; 53(10 Suppl):S26-28.
  369. Zhu YX, Suen TC, Zhang N, Lu M, Goss PE, Hawley RG. The HOX11 oncoprotein represses transcription. Blood. 1998; 92(10 Suppl 1):1 pt 2.
  370. Goss PE. Pre-clinical and clinical review of vorozole, a new third generation aromatase inhibitor. Breast Cancer Res Treat. 1998; 49 Suppl 1:S59-65; discussion S73-7.
    View in: PubMed
  371. Goss PE, Sierra S. Radiation-induced breast cancer after treatment for Hodgkin’s disease. Comment in J Clin Oncol. 1998; 16(6):2285-7.
  372. Goss PE & Tye LM. Hormones and Cancer. Basic Science of Oncology. Tannock IF, Hill RP, eds. 1998; 263-94.
  373. Gervais-Fagnou D, Laperriere N, Pintilie M, Goss PE. Breast cancer in women following supradiaphragmatic irradiation for Hodgkin’s disease. Breast Cancer Res Treat. 1998; 50(3):300, A418.
  374. Suen TC, Goss PE. An important cis-acting element and trans-acting factor on the bi-directional human BRCA1 promoter. Abstracts of the Cold Spring Harbor Symposium on Cancer Genetics and Tumor Suppressor Genes. 1998; 251.
  375. Abraham R, Arts K, Roitman D, Goss PE, Crump M. Abnormalities of bone densitometry in pre-menopausal women following HDCT for poor prognosis stage II breast disease. Breast Cancer Res Treat. 1998; 50(3):248, A149.
  376. 1997.
  377. Goss PE, Tye LM. Anastrozole: a new selective nonsteroidal aromatase inhibitor. Oncology (Williston Park). 1997 Nov; 11(11):1697-703; discussion 1707-8.
    View in: PubMed
  378. 1997.
  379. Goss PE, Reid CL, Bailey D, Dennis JW. Phase IB clinical trial of the oligosaccharide processing inhibitor swainsonine in patients with advanced malignancies. Clin Cancer Res. 1997 Jul; 3(7):1077-86.
    View in: PubMed
  380. 1997.
  381. 1997.
  382. Goss PE, Winer E, Tannock I, Schwartz LH, Kremer AB. Vorozole vs. Megace® in postmenopausal patients with metastatic breast carcinoma who had relapsed following tamoxifen. Proc Annu Meet Am Soc Clin Oncol. 1997; 16:A542.
  383. Patnaik A, MacKinnon J, Goss PE, Stewart AK, Keating A, Crump M. Phase I-II trial of cyclophosphamide (C), mitroxantrone (M) and escalated doses of carboplatin (Car) supported by peripheral blood stem cells in women with metastatic breast cancer (MBC). Proc Annu Meet Am Soc Clin Oncol. 1997; 16:A390.
  384. Biagi J, Grief C, Gullane P, Brown D, Bailey D, Gospodarowicz M, Brennan J, Goss PE. Extranodal non-Hodgkin’s lymphoma of the head and neck. Proc Annu Meet Am Soc Clin Oncol. 1997; 16:A92.
  385. Gwyn K, Hao Y, Miller A, Goss PE. The clinico-pathologic presentation of breast cancer in postmenopausal women exposed to hormone replacement therapy (HRT). Proc Annu Meet Am Soc Clin Oncol. 1997; 16:A469.
  386. Reid C, Pintilie M, Goncalves S, Catton J, Lim R, Miller N, Goss PE. A review of 229 male breast cancer patients presenting to the Princess Margaret Comprehensive Cancer Centre. Proc Annu Meet Am Soc Clin Oncol. 1997; 16:A476.
  387. Goss PE, Oza A, Blackstein M, Kaizer L, Sterns EE, Verma S, Nabholtz J, Palmer P, Crump M, Reid C, Tye L. A phase II study of liarozole fumarate in postmenopausal women with metastatic breast cancer. Proc Annu Meet Am Soc Clin Oncol. 1997; 16:A529.
  388. Chan A, Pintilie M, Vallis K, Girouard C, Goss PE. A review of 1176 women with early-onset breast cancer, EOBC, (<35 yrs). Proc Annu Meet Am Soc Clin Oncol. 1997; 16:A474.
  389. 1997.
  390. 1997.
  391. 1997.
  392. King BL, Peng HQ, Goss P, Huan S, Bronson D, Kacinski BM, Hogg D. Repeat expansion detection analysis of (CAG)n tracts in tumor cell lines, testicular tumors, and testicular cancer families. Cancer Res. 1997 Jan 15; 57(2):209-14.
    View in: PubMed
  393. 1997.
  394. 1997.
  395. 1997.
  396. 1997.
  397. Jin T, Zhang X, Goss PE. Aromatase inhibition in breast cancer: studies of an evolutionarily conserved domain of human aromatase promoter PII. Breast Cancer Res Treat. 1997; 46(1):92, A382.
  398. Jin T, Zhang S, Zhang X, Goss PE. POU homeobox gene expression in malignant and non-malignant breast epithelial cell lines. Breast Cancer Res Treat. 1997; 46(1):92, A381.
  399. Suen TC, Goss PE. A negative regulatory element on the neu gene promoter. Proceedings of AACR Special Conference on Disrupted Transcription Factors in Cancer. 1997; B32.
  400. Goss PE. Vorozole – A viewpoint [guest commentary]. Drugs & Aging. 1997; 11(3):251.
  401. 1997.
  402. Goss PE, Fine S, Gelmon K, Rudinskas L, Ottaway J, Myles J, James K, Paul K, Rodgers A, Pritchard KI. Phase I studies of fluorouracil, doxorubicin and vinorelbine without (FAN) and with (SUPERFAN) folinic acid in patients with advanced breast cancer. Cancer Chemother Pharmacol. 1997; 41(1):53-60.
    View in: PubMed
  403. 1996.
  404. Liu G, Crump M, Goss PE, Dancey J, Shepherd FA. Prospective comparison of the sclerosing agents doxycycline and bleomycin for the primary management of malignant pericardial effusion and cardiac tamponade. J Clin Oncol. 1996 Dec; 14(12):3141-7.
    View in: PubMed
  405. 1996.
  406. 1996.
  407. Goss PE, Stewart A, Couture F, Burkes R, Gluck S, Kaizer L, Charpentier D, Dulude H, Gallant G. A phase II study of paclitaxel (P) in patients with refractory lymphomas. Proc Annu Meet Am Soc Clin Oncol. 1996; 15:A1286.
  408. Crump M, Kamel-Reid S, Padmore R, Bailey D, McEachern J, Shepherd F, Goss PE, Scott JG, Baker MA. Primary mediastinal non-Hodgkin’s lymphoma (NHL): homogeneous molecular phenotype and favourable clinical outcome. Proc Annu Meet Am Soc Clin Oncol. 1996; 15:A1256.
  409. Goss PE, Baker M, Reid C, Dennis J. A phase IB clinical trial of the oligosaccharide processing inhibitor swainsonine in patients with advanced malignancies. Proc Annu Meet Am Soc Clin Oncol. 1996; 15:A1566.
  410. Goss PE, Gwyn K, Chu Q, Hao Y. Effects of hormone replacement therapy (HRT) on the clinico-pathologic presentation of breast cancer. Proc Annu Meet Am Soc Clin Oncol. 1996; 15:A260.
  411. Goss PE, Oza A, Blackstein M, Kaizer L, Sterns EE, Verma S, Nabholtz J, Langenaeken C, DeCoster R, Fulop G, Crump M, Reid C. A phase II study of liarozole fumarate in postmenopausal women with metastatic breast cancer. Proc Annu Meet Am Soc Clin Oncol. 1996; 15:A156.
  412. Norris B, Pritchard K, James K, Myles J, Bennett K, Marlin S, Skillings J, Findlay B, Goss PE, Latreille J, Lopez P, Osoba D, Rodgers A. A phase III comparative study of vinorelbine (VNB) combined with doxorubicin (DOX) vs. doxorubicin alone in metastatic/recurrent breast cancer (MBC): a National Cancer Institute of Canada (NCIC-CTG) study. Proc Annu Meet Am Soc Clin Oncol. 1996; 15:A59.
  413. Phelan CM, Lancaster JM, Tonin P, Gumbs C, Cochran C, Carter R, Ghadirian P, Perret C, Moslehi R, Dion F, Faucher MC, Dole K, Karimi S, Foulkes W, Lounis H, Warner E, Goss P, Anderson D, Larsson C, Narod SA, Futreal PA. Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nat Genet. 1996 May; 13(1):120-2.
    View in: PubMed
  414. Goss PE, Hack T, Cohen L, Ritvo P, Katz J. Long term physical and psychological morbidity of axillary lymph node dissection (ALND) in patients with breast cancer. Proc Annu Meet Am Soc Clin Oncol. 1996; 15:A158.
  415. Yu E, Goss P, Cusimano RJ, Winton T, Rakowski H, Flora JS. An intracardiac mass presenting as atrial fibrillation in a patient with testicular carcinoma. Can J Cardiol. 1996 Mar; 12(3):303-5.
    View in: PubMed
  416. Goss PE, Crump M, Reid C, Oza A, Blackstein M, Kaizer L, Sterns EE, Goel R, Verma S, Nabholtz J, Langenaeken C, DeCoster R, Fulop G. A phase II study of liarozole fumarate - a new P450 retinoic acid hydroxylase inhibitor in postmenopausal women with metastatic breast cancer. Breast Cancer Res Treat. 1996; 41(3):290, A521.
  417. Crump M, Goss PE, Prince M, Girouard C. Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes. J Clin Oncol. 1996 Jan; 14(1):66-9.
    View in: PubMed
  418. Orcheson L, Boerner S, Gorman D, Thompson LU, Goss PE. Expression of the proliferation antigen Ki-67 and estrogen (ER) and progesterone (PR) receptors in paraffin-embedded cell blocks correlate with corresponding histologic sections of breast carcinoma. Breast Cancer Res Treat. 1996; 41(254):A225.
  419. 1996.
  420. Goss PE, Goel R, Oza A, Blackstein M, Kaizer L, Sterns EE, Verma S, Nabholtz J, Langenaeken C, Crump M. A phase II study of liarozole fumarate in postmenopausal women with metastatic breast cancer. Breast Cancer Res Treat. 1996; 37 Suppl(71):A124.
  421. Goss PE, Hack T, Cohen L, Ritvo P, Katz J, Orcheson L. Long term physical and psychological morbidity of axillary lymph node dissection (ALND) in patients with breast cancer. Breast Cancer Res Treat. 1996; 41(3):274, A408.
  422. Goss PE, Baker MA, Carver JP, Dennis JW. Inhibitors of carbohydrate processing: A new class of anticancer agents. Clin Cancer Res. 1995 Sep; 1(9):935-44.
    View in: PubMed
  423. 1995.
  424. Peng HQ, Bailey D, Bronson D, Goss PE, Hogg D. Loss of heterozygosity of tumor suppressor genes in testis cancer. Cancer Res. 1995 Jul 1; 55(13):2871-5.
    View in: PubMed
  425. Goss P, Burkes R, Rudinskas L, King M, Chow W, Myers R, Davidson M, Poldre P, Crump M, Sutton D, et al. A phase II trial of prednisone, oral etoposide, and novantrone (PEN) as initial treatment of non-Hodgkin's lymphoma in elderly patients. Leuk Lymphoma. 1995 Jun; 18(1-2):145-52.
    View in: PubMed
  426. Goss P, Shepherd F, Scott JG, Baker M, Sutton D, Sutcliffe S. DICE (dexamethasone, ifosfamide, cisplatin, etoposide) as salvage therapy in non-Hodgkin's lymphomas. Leuk Lymphoma. 1995 Jun; 18(1-2):123-9.
    View in: PubMed
  427. Crump M, Prince M, Goss PE. Outcome of extensive evaluation of women with ³ 10 positive axillary lymph nodes prior to adjuvant therapy for breast cancer. Proc Annu Meet Am Soc Clin Oncol. 1995; 14:A106.
  428. 1995.
  429. Goss PE, Reid C, Granovsky M, Warren C, Dennis JW. Inhibitors of oligosaccharide processing as anti-cancer agents: mechanistic and clinical studies. Proc Annu Meet Am Assoc Cancer Res. 1995; 36:A2340.
  430. 1995.
  431. Goss PE, Clark RM, Ambus U, Weizel HA, Wadden NA, Crump M, Walde D, Tye LM, De Coster R, Bruynseels J. Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen. Clin Cancer Res. 1995 Mar; 1(3):287-94.
    View in: PubMed
  432. 1995.
  433. 1995.
  434. Prince M, Imrie K, Keating A, Trip K, Goss PE, Crump M. Peripheral blood progenitor cell mobilization with cyclophosphamide, adriamycin, 5-flurouracil (CAF) and G-CSF: ability to support multiple cycles of high-dose chemotherapy. Exp Hematol. 1995; 23(8):49.
  435. Prince HM, Imrie K, Keating A, Goss PE, Stewart AK, Crump M. Cyclophosphamide, adriamycin, 5-flurouracil (CAF) and G-CSF mobilization achieves high peripheral blood progenitor cell (PBPC) yield which can support multiple cycles of high dose chemotherapy. Blood. 1995; 86(10 Suppl 1):1602.
  436. 1994.
  437. Goss PE, Gwyn KM. Current perspectives on aromatase inhibitors in breast cancer. J Clin Oncol. 1994 Nov; 12(11):2460-70.
    View in: PubMed
  438. Goss PE, Clark R, Ambus U, Weizel H, Crump M, Martell M, Wadden N, Shepherd F, Walde D, Tye L, DeCoster R. Phase II study of Vorozole (R 83842) a new aromatase inhibitor in postmenopausal women with advanced breast cancer. Proc Annu Meet Am Soc Clin Oncol. 1994; 13:A156.
  439. 1994.
  440. Goss PE, Schwertfeger L, Blackstein ME, Iscoe NA, Ginsberg RJ, Simpson WJ, Jones DP, Shepherd FA. Extragonadal germ cell tumors. A 14-year Toronto experience. Cancer. 1994 Apr 1; 73(7):1971-9.
    View in: PubMed
  441. Goss PE, Burkes R, Rudinskas L, King M, Chow W, Myers R, Davidson M, Poldre P, Crump M, Sutton D, et al. Prednisone, oral etoposide, and novantrone for treatment of non-Hodgkin's lymphoma: a preliminary report. Semin Hematol. 1994 Apr; 31(2 Suppl 3):23-9.
    View in: PubMed
  442. Goss PE, Baptiste J, Fernandes B, Baker M, Dennis JW. A phase I study of swainsonine in patients with advanced malignancies. Cancer Res. 1994 Mar 15; 54(6):1450-7.
    View in: PubMed
  443. Baptista JA, Goss P, Nghiem M, Krepinsky JJ, Baker M, Dennis JW. Measuring swainsonine in serum of cancer patients: phase I clinical trial. Clin Chem. 1994 Mar; 40(3):426-30.
    View in: PubMed
  444. 1994.
  445. Pérez Carrión R, Alberola Candel V, Calabresi F, Michel RT, Santos R, Delozier T, Goss P, Mauriac L, Feuilhade F, Freue M, et al. Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer. Ann Oncol. 1994; 5 Suppl 7:S19-24.
    View in: PubMed
  446. 1994.
  447. 1994.
  448. Korczak B, Goss P, Fernandez B, Baker M, Dennis JW. Branching N-linked oligosaccharides in breast cancer. Adv Exp Med Biol. 1994; 353:95-104.
    View in: PubMed
  449. Korczak B, Goss PE, Fernandes B, Baker M, Dennis JW. Branching N-linked oligosaccharides in breast cancer. Antigen and Antibody Molecular Engineering in Breast Cancer Diagnosis and Treatment. Ceriani RL, ed. 1994; 95-104.
  450. Goss PE, Clark R, Ambus U, Weizel H, Shepherd F, Wadden N, Lipa M, Crump M, Walde D, Tye L, DeCoster R. Phase II study of vorozole (R83842) a new aromatase inhibitor in postmenopausal women with advanced breast cancer. Breast Cancer Res Treat. 1994; 32(Suppl 67):A154.
  451. 1993.
  452. 1993.
  453. Gibson S, Leung B, Squire JA, Hill M, Arima N, Goss P, Hogg D, Mills GB. Identification, cloning, and characterization of a novel human T-cell-specific tyrosine kinase located at the hematopoietin complex on chromosome 5q. Blood. 1993 Sep 1; 82(5):1561-72.
    View in: PubMed
  454. Peng HQ, Hogg D, Malkin D, Bailey D, Gallie BL, Bulbul M, Jewett M, Buchanan J, Goss PE. Mutations of the p53 gene do not occur in testis cancer. Cancer Res. 1993 Aug 1; 53(15):3574-8.
    View in: PubMed
  455. 1993.
  456. Goss PE and The Metro Toronto Lymphoma Group. PEN (Prednisone, Etoposide and Novantrone) for treatment of non-Hodgkin's lymphoma (NHL) in elderly patients. Proc Annu Meet Am Soc Clin Oncol. 1993; 12:A1259.
  457. Goss PE. Non-Hodgkin's lymphomas in elderly patients. Leuk Lymphoma. 1993 Jun; 10(3):147-56.
    View in: PubMed
  458. Peng HQ, Goss PE, Bailey D, Malkin D, George D, Bronson D, Hogg D. Tumor suppressor genes in germ cell tumors (GCT) of the testis. Proc Annu Meet Am Soc Clin Oncol. 1993; 12:A1259.
  459. Goss PE, Baker M, Baptista J, Krepinsky JJ, Deleon V, Korczak B, Fernandes B, Dennis J. Phase I clinical trial of swainsonine in patients with advanced malignancies. Proc Annu Meet Am Soc Clin Oncol. 1993; 12:A385.
  460. 1993.
  461. Goss PE. New perspectives in the treatment of non-Hodgkin's lymphoma. Semin Oncol. 1992 Dec; 19(6 Suppl 12):23-9.
    View in: PubMed
  462. 1992.
  463. 1992.
  464. 1992.
  465. Shepherd FA, Evans WK, Goss PE, Latreille J, Logan D, Maroun J, Stewart D, Warner E, Paul K. Ifosfamide, cisplatin, and etoposide (ICE) in the treatment of advanced non-small cell lung cancer. Semin Oncol. 1992 Feb; 19(1 Suppl 1):54-8.
    View in: PubMed
  466. Shepherd FA, Laskey J, Evans WK, Goss PE, Johansen E, Khamsi F. Cushing's syndrome associated with ectopic corticotropin production and small-cell lung cancer. J Clin Oncol. 1992 Jan; 10(1):21-7.
    View in: PubMed
  467. Hoffken K, Chacon R, Dombernowsky P, Goss PE, Willemse P, Engan T, Bonte J, Tubiana-Hulin M, Lopez JJ, Elomaa I, Chaudri H, Trunet P. Fadrozol hydrochloride (CGS 16949 A), a double-blind dose-finding study in postmenopausal patients with advanced breast cancer. Ann Oncol. 1992; 3(Suppl 5):76.
  468. Shepherd FA, Goss PE, Rusthoven J, Eisenhauer EA. Phase I trial of granulocyte-macrophage colony-stimulating factor with high-dose cisplatin and etoposide for treatment of small-cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group. J Natl Cancer Inst. 1992 Jan 1; 84(1):59-60.
    View in: PubMed
  469. Korczak B, Goss PE, Fernandes B, Baker M, Dennis JW. Branching N-linked oligosaccharides in breast cancer. Proceedings of the 5th International Workshop on Breast Cancer Research and Immunology. Ceriani RL, ed. 1992.
  470. Goss PE, Schwertfeger L, Shepherd F, Ginsberg R. Extragonadal Germ Cell Tumors (EGCT's): a ten year Toronto experience. Proc Annu Meet Am Soc Clin Oncol. 1991; 10:A591.
  471. Shepherd F, Rusthoven J, Goss PE, Eisenhauer E. Phase I-II trial of high dose cisplatin, etoposide and GM-CSF for small cell lung cancer (SCLC). Proc Annu Meet Am Soc Clin Oncol. 1991; 10:A864.
  472. Shepherd F, Goss PE, Evans WK, Amdemichael E, Chalvardjian P, Johnson S, Coates R, Baker M. Treatment of small cell lung cancer (SCLC) in the elderly. Proc Annu Meet Am Soc Clin Oncol. 1991; 10:A821.
  473. Shepherd FA, Burkes RL, Paul KE, Goss PE. A phase II study of 4'-epirubicin in the treatment of poor-risk Kaposi's sarcoma and AIDS. AIDS. 1991 Mar; 5(3):305-9.
    View in: PubMed
  474. Shepherd FA, Ginsberg R, Patterson GA, Feld R, Goss PE, Pearson FG, Todd TJ, Winton T, Rubinger M, Johansen E. Is there ever a role for salvage operations in limited small-cell lung cancer? J Thorac Cardiovasc Surg. 1991 Feb; 101(2):196-200.
    View in: PubMed
  475. Goss PE, Shepherd FA, Scott JG, Warner E, Baker MA, Sutton D, Farquharson HA, Buick S, Sutcliffe S. Dexamethasone/ifosfamide/cisplatin/etoposide (DICE) as therapy for patients with advanced refractory non-Hodgkin's lymphoma: preliminary report of a phase II study. Ann Oncol. 1991 Jan; 2 Suppl 1:43-6.
    View in: PubMed
  476. Latreille J, Blackstein M, Goss PE, Guevin R, Sutherland D, Brousseau S, Gupta S. Final results of a phase III trial of CMF vs. CEF in metastatic breast cancer. A multicentre study. Eur J Cancer. 1991; 27(Suppl 2):S57, A315.
  477. 1991.
  478. Stewart AK, Shepherd FA, Goss PE, Warner E, Bailey DJ, Baker MA. Gastrointestinal non-Hodgkin's lymphoma. Leuk Lymph. 1991; 4:167-76.
  479. Goss PE, Bulbul MA. Familial testicular cancer in five members of a cancer-prone kindred. Cancer. 1990 Nov 1; 66(9):2044-6.
    View in: PubMed
  480. Goss PE, Shepherd F, Buick S, Scott J, Hogg D, Sutcliffe S, Warner E, Sutton D, Baker M. Phase II trial of DICE (Dexamethasone, Ifosfamide, Cisplatin, and Etoposide) in patients with refractory non-Hodgkin's lymphoma (NHL). Proc Annu Meet Am Soc Clin Oncol. 1990; 9:A1028.
  481. Shepherd F, Goss PE, Latreille J, Stewart D, Logan D, Maroun J, Evans W, Paul K. Ifosfamide, cisplatin, and etoposide (ICE) for non-small cell lung cancer (N-SCLC). Proc Annu Meet Am Soc Clin Oncol. 1990; 9:A929.
  482. 1990.
  483. Shepherd FA, Goss PE, Latreille J, Stewart D, Logan D, Evans WK, Maroun J, Warner E. A phase II study of ifosfamide, cisplatin, etoposide in patients with advanced non-small cell lung cancer: a preliminary report. Semin Oncol. 1990 Apr; 17(2 Suppl 4):19-23.
    View in: PubMed
  484. 1990.
  485. Stewart AK, Shepherd FA, Goss PE, Scott JG, Baker MA, Farquharson HA, Warner E. Treatment of gastrointestinal non-Hodgkin's lymphoma (GI-NHL). Clin Invest Med. 1990; 13:B69, A427.
  486. Goss PE, Shepherd F, Buick S, Scott J, Hogg D, Sutcliffe S, Warner E, Sutton D, Baker M. Phase II trial of DICE (Dexamethasone, Ifosfamide, Cisplatin, and Etoposide) in patients with refractory non-Hodgkin's Lymphoma (NHL). Clin Invest Med. 1990; 13:B69, A428.
  487. Shepherd F, Goss PE, Evans W, Amdemichael E, Chalvardjian P, Hogg-Johnson S, Coates R. Treatment of small cell lung cancer (SCLC) in the elderly. 1990; 13:B69, A431.
  488. Shepherd F, Goss PE, Latreille J, Stewart D, Logan D, Maroun J, Evans W, Paul K. Ifosfamide, Cisplatin, and Etoposide (ICE) for non-small cell lung cancer (NSCLC). Clin Invest Med. 1990; 13:B69, A430.
  489. Goss PE, Schwertfeger L, Shepherd F, Ginsberg R, Blackstein M, Warner E, Simpson WJ, Jones D. Extragonadal germ cell tumors (EGCT'S): a ten year Toronto experience. Clin Invest Med. 1990; 13:B69, A436.
  490. Shepherd FA, Hogg-Johnson S, Fleshner N, Read SE, Fanning MM, Johnson K, Goss P, Coates RA. Kaposi's sarcoma and AIDS: a variable spectrum. Clin Invest Med. 1989 Dec; 12(6):367-73.
    View in: PubMed
  491. Siminoski K, Goss P, Drucker DJ. The Cushing syndrome induced by medroxyprogesterone acetate. Ann Intern Med. 1989 Nov 1; 111(9):758-60.
    View in: PubMed
  492. Goss PE, Shepherd FA, Burkes R, Paul K. Phase II study of epirubicin in the treatment of Kaposi's sarcoma and AIDS. Proc Annu Meet Am Soc Clin Oncol. 1989; 8:A5.
  493. 1989.
  494. Burkes R, Shepherd F, Blackstein M, Goss PE, Lassus M. Hepatic arterial infusion (HAI) of 4’epirubicin (EPI) in the treatment of primary hepatocellular carcinoma (HCC). Proc Annu Meet Am Soc Clin Oncol. 1988; 7:A398.
  495. 1988.
  496. Coombes RC, Goss PE, Dowsett M, Hutchinson G, Cunningham D, Jarman M, Brodie AM. 4-Hydroxyandrostenedione treatment for postmenopausal patients with advanced breast cancer. Steroids. 1987 Jul-Sep; 50(1-3):245-52.
    View in: PubMed
  497. Dowsett M, Goss PE, Powles TJ, Hutchinson G, Brodie AM, Jeffcoate SL, Coombes RC. Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route. Cancer Res. 1987 Apr 1; 47(7):1957-61.
    View in: PubMed
  498. Coombes RC, Powles TJ, Goss PE, Cunningham D, Hutchinson G, Dowsett M, Brodie AM. Clinical studies with 4-hydroxyandrostenedione in breast cancer patients. Monogr Ser Eur Organ Res Treat Cancer. 1987; 18:81-7.
  499. Coombes RC, Goss PE, Dowsett M, Hutchinson G, Cunningham D, Jarman M, Brodie AM. 4-Hydroxyandrostenedione treatment for post-menopausal patients with advanced breast cancer. Tumor Diagnostik & Therapie. 1987; 8:271-3.
  500. Brodie AM, Wing LY, Goss P, Dowsett M, Coombes RC. Aromatase inhibitors and their potential clinical significance. J Steroid Biochem. 1986 Nov; 25(5B):859-65.
    View in: PubMed
  501. Wilkinson JR, Williams JC, Singh D, Goss PE, Easton D, Coombes RC. Response of nitrosomethylurea-induced rat mammary tumor to endocrine therapy and comparison with clinical response. Cancer Res. 1986 Sep; 46(9):4862-5.
    View in: PubMed
  502. Goss PE, Powles TJ, Dowsett M, Hutchison G, Brodie AM, Gazet JC, Coombes RC. Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report. Cancer Res. 1986 Sep; 46(9):4823-6.
    View in: PubMed
  503. Seago A, Goss PE, Griggs LJ, Jarman M. Pyridoglutethimide [3-ethyl-3-(4-pyridyl)-piperidine-2,6-dione], an analogue of aminoglutethimide. Metabolism and pharmacokinetics. Biochem Pharmacol. 1986 Sep 1; 35(17):2911-6.
    View in: PubMed
  504. Goss PE, Ashley S, Powles TJ, Coombes RC. High-dose oral medroxyprogesterone acetate in heavily pretreated patients with metastatic breast cancer. Cancer Treat Rep. 1986 Jun; 70(6):777-9.
    View in: PubMed
  505. Goss PE, Jarman M, Wilkinson JR, Coombes RC. Metabolism of the aromatase inhibitor 4-hydroxyandrostenedione in vivo. Identification of the glucuronide as a major urinary metabolite in patients and biliary metabolite in the rat. J Steroid Biochem. 1986 Feb; 24(2):619-22.
    View in: PubMed
  506. Brodie AM, Wing LY, Goss P, Dowsett M, Coombes RC. Aromatase inhibitors and the treatment of breast cancer. J Steroid Biochem. 1986 Jan; 24(1):91-7.
    View in: PubMed
  507. Goss PE, Jarman M, Griggs LJ. Metabolism of aminoglutethimide in humans: quantification and clinical relevance of induced metabolism. Br J Cancer. 1985 Feb; 51(2):259-62.
    View in: PubMed
  508. 1984.
  509. Coombes RC, Goss P, Dowsett M, Gazet JC, Brodie A. 4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer. Lancet. 1984 Dec 1; 2(8414):1237-9.
    View in: PubMed
  510. Goss PE, Coombes RC, Powles TJ, Dowsett M, Brodie AM. 4-hydroxyandrostenedione treatment for postmenopausal patients with advanced breast cancer. Breast Cancer Res Treat. 1984; 4:352, A71.
  511. Goss PE, Coombes RC. Hormonal agents. Cancer Topics. 1984; 4:122-3.
  512. Jarman M, Foster AB, Baker MH, Goss PE, Leung CS, Leung OT, McCague R, Rowlands MG, Coombes RC, LeClerq G. . The development of new anti-endocrine type drugs. Cancer Chemotherapy and Selective Drug Development. In: Harrap KR, Davis W, Calvert AH, eds. 1984; 485-9.
  513. Jarman M, Foster AB, Goss PE, Griggs LJ, Howe I, Coombes RC. Metabolism of aminoglutethimide in humans: identification of hydroxylaminoglutethimide as an induced metabolite. Biomed Mass Spectrom. 1983 Nov; 10(11):620-5.
    View in: PubMed
  514. Goss P, Parsons PG. The effect of hyperthermia and melphalan on survival of human fibroblast strains and melanoma cell lines. Cancer Res. 1977 Jan; 37(1):152-6.
    View in: PubMed
  515. Goss P, Parsons PG. Temperature-sensitive DNA repair of ultraviolet damage in human cell lines. Int J Cancer. 1976 Mar 15; 17(3):296-303.
    View in: PubMed
  516. Parsons PG, Goss P, Pope JH. Detection in human melanoma cell lines of particles with some properties in common with RNA tumour viruses. Int J Cancer. 1974 May 15; 13(5):606-18.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Goss's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
See all (589) concept(s)
_
Co-Authors
See all (18) people
_
Similar People
See all (60) people
_
Same Department
Search Department
Physical Neighbors
_